31 July 2013 – final results
The group has revealed its annual results to 30 April, revealing that the loss for the year was reduced to £1.0m (2012: £2.7m) although given the early stage of the group’s development these figures are not really relevant. The group has continued to make significant progress with its Parsortix medical device upon which the company has invested so much. This has been well-received by the group’s partners and is now being evaluated by key opinion leaders in the fields of cancer diagnosis and treatment. Continue to BUY.